Physician profile
Thomas E Gillette
NPI 1952387086
$2,443.96
in general payments reported to CMS, 2019-2025
12 companies · $310 in 2025
The $310 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $468 · 2020: $128 · 2021: $58.67 · 2022: $315 · 2023: $1,003 · 2024: $162 · 2025: $310.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,475.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,474.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lensar, INC. | $714.78 | 2023 | Lensar Laser System |
| Johnson & Johnson Surgical Vision, INC. | $385.53 | 2019-2022 | |
| Alcon Vision LLC | $262.48 | 2022-2023 | Hydrus Microstent |
| Tarsus Pharmaceuticals, INC. | $209.95 | 2024-2025 | Xdemvy |
| Allergan, INC. | $192.26 | 2019-2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $148.60 | 2019-2020 | |
| Ocular Therapeutix, INC. | $148.30 | 2023 | Dextenza |
| Abbvie INC. | $142.07 | 2025 | |
| Bausch & Lomb Americas INC. | $120.21 | 2024 | Miebo |
| Sight Sciences, INC. | $62.09 | 2021-2022 | |
| Biotissue Holdings INC. | $36.10 | 2021 | |
| Kala Pharmaceuticals, INC. | $21.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Gillette listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.